Keywords
MGMT
1p/ 19q deletion
signaling pathways
How to Cite
Abstract
Glioblastoma multiforme is the most common central nervous system (CNS) primary tumor in men. Its incidence in Europe lies between 3 to 4 cases per 100,000 inhabitants and it represents 25% of all the CNS tumors and 50% of the primary tumors. Less than 3% of all patients diagnosed with glioblastoma multiforme survive more than 4 years and the average survival is of 6 months. Studies aiming to increase the survival rate, as well as to achieve longer asymptomatic periods are being carried out at present.
The main goal of this review is to offer a brief recount on the progress in the treatment of glioblastoma multiforme, focusing on genetic therapy. The consulted literature showed, that there are only two types of mutations capable of defining the prognosis of this disease at this point; one is the presence of O6-methylguanine-DNA methyltransferase protein expression (MGMT) and the 1p/ 19q deletion on which we will emphasize in the course of this document.
de Angelis LM. Brain tumors. NEJM. 2001;344:114.
Scherer H. The forms of growth in Gliomas and their practical significance Brain. 1940;40:631-5.
Teixeira MM, García I, Portela I, Cernuda M, Oliveira C, Albano J, et al.
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. Int J Clin Pharmacol Res. 2002; 22:19-22.
Perry A, Anderl K, Borell TJ, Kimmel DW, Wang CH, O’Fallon JR, Feuerstein BG, Scheithauer BW, Jenkins RB. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol. 1999;112: 801-9.
Ruano Y. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol. 2009;131:257-63.
Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, Segatto O, Brennan C, Elferink LA, Wang YA, Chin L, DePinho RA.Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6912-7
Jha P, Agarwal S. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet Cytogenet. 2010;198:126-34.
Lassman AB, Abrey LE, Gilbert MR. Response of glioblastomas to EGFR
kinase inhibitors. N Engl J Med. 2006;354:525-6.
Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth
factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem. 2009;9:703-15.
Brandsma D. Molecular targeted therapies and chemotherapy in malignant gliomas. Current Opinion in Oncology. 2007;19:598-605.
Idbaih A. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion in Oncology. 2007;19:606-11.
Ostman A. PDGF receptors - mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004; 15:275-86.
Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol. 2005;16:1702-8.
Nagane M, Kobayashi K, Ohnishi A, Shimizu S, Shiokawa Y. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. Dec 2007;37(12):897-906.
Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol. 2006;60:740-3.
Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, et al. Phase I trial of temozolomide plus O6- benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178-87.
Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine- DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003;13:176-84.
van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27:5881-6.
Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO. Correlations between O6- methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent
oligodendroglioma: a prospective GICNO study. J Clin Oncol. 2006;24:
-53.
Keime-Guibert F, Chinot O, Taillandier L. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527-35.
Uyl-de Groot CA, Stupp R, van der Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev Pharmacoecon Outcomes Res. 2009;9:235-41.
Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-66.
Nutt CL, Noble M, Chambers AF, Cairncross JG. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas
and astrocytomas to chemotherapy. Cancer Res. 2000;60: 4812-8.
Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009;11:167-75.
Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, et
al. Response and progression in recurrent malignant glioma. Neuro Oncol. 1999;1:282-8.
Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, et al. The 1pencoded protein stathmin and resistance of malignant gliomas to
nitrosoureas. J Natl Cancer Inst. 2007;99:639-52.
Idbaih A, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, et al. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. Neuropathology. 2008;28:440-3.
Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle- Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K. Temozolomide for lowgrade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68:1831-6.
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006; 24:2715-22.
van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor
Group Study 26971. J Clin Oncol. 2003;21:2525-8.
Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY.
Bevacizumab salvage therapy following progression in high-grade glioma
patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncology Advance Access published online on February 14, 2010
Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol. 2004;22:1598-604.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
Takahashi S, Hirose Y, Ikeda E, Fukaya R, Kawase T. Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma. Case report. J Neurosurg. 2007;106:488-94.
Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide- induced toxicity in a p53- independent manner in human glioblastoma cells. Cancer Res. 2001; 61:5843-9.
Finlay JL, August C, Packer R, Zimmerman R, Sutton L, Freid A, et al.
High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neurooncol. 1990; 9:239-48.
Kreklau EL, Limp-Foster M, Liu N, Xu Y, Kelley MR, Erickson LC. A novel fluorometric oligonucleotide assay to measure O(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res. 2001;29:2558-66.
Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, et al. A phase II study of intensified chemotherapy
alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008;89:187-93.
Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S, Pollo B, Savoiardo M, Solero CL, Valsecchi MG; Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico)
Istituto Neurologico Carlo Besta. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008;10: 79-87.
Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D. Correlation between O6-methylguanine- DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007; 25:1470-5.
Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS. Temozolomide- mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006;12:4738-46.
Gerson SL. MGMT: its role in cancer etiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296-307.
Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, et al. Quantitative analysis of O6- alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther. 2006;5:2531-9.
Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer. 2003;89:248-51.
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al.
A phase II study of temozolomide Vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-93.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.